Søren D Ostergaard1, Per Bech2, Madhukar H Trivedi3, Stephen R Wisniewski4, A John Rush5, Maurizio Fava6. 1. Research Unit Department P, Aarhus University Hospital, Risskov, Skovagervej 2, DK-8240 Risskov, Denmark; Unit For Psychiatric Research, Aalborg Psychiatric Hospital, Aalborg University Hospital, Aalborg, Denmark; Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: soeoes@rm.dk. 2. Psychiatric Research Unit, Psychiatric Center North Zealand, Copenhagen University Hospital, Hillerød, Denmark. 3. University of Texas, Southwestern Medical School, Dallas, TX, USA. 4. Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA. 5. Clinical Sciences, Duke-NUS, Singapore, Singapore. 6. Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Abstract
BACKGROUND: Most depression rating scales are multidimensional and the resulting heterogeneity may impede identification of coherent biomarkers. The aim of this study was to compare the psychometric performance of the multidimensional 17-item Hamilton Depression Rating Scale (HAM-D17) and the 30-item Inventory of Depressive Symptomatology (IDS-C30) to that of their unidimensional six-item melancholia subscales (HAM-D6 and IDS-C6). METHODS: A total of 2242 subjects from level 1 (citalopram) of the Sequenced Treatment Alternatives to Relieve Depression (STAR* study were included in the analysis. Symptom change, response and remission rates were compared for HAM-D6 versus HAM-D17 and for IDS-C6 versus IDS-C30. The changes in total scores on these scales were compared to the change in Quality of Life Enjoyment and Satisfaction Questionnaire (QLES-Q) score using correlation analysis. RESULTS: The response to treatment was significantly greater according to the HAM-D6 and IDS-C6. Furthermore, the correlation of changes in depression-ratings with changes in QLES-Q scores were comparable for the subscales and full scales. LIMITATIONS: STAR*D was not designed to answer the research questions addressed in this analysis. CONCLUSIONS: Our findings indicate that the HAM-D6 and IDS-C6 melancholia scales capture a coherent construct in depression. The syndrome reflected in these scales is unidimensional, sensitive to specific pharmacological intervention, and therefore likely to have biological validity. We therefore believe that "melancholia" thus defined could be a valuable construct under the Research Domain Criteria (RDoC), which specifically aims at identifying the neurobiology underlying mental disorders and providing drugable targets.
BACKGROUND: Most depression rating scales are multidimensional and the resulting heterogeneity may impede identification of coherent biomarkers. The aim of this study was to compare the psychometric performance of the multidimensional 17-item Hamilton Depression Rating Scale (HAM-D17) and the 30-item Inventory of Depressive Symptomatology (IDS-C30) to that of their unidimensional six-item melancholia subscales (HAM-D6 and IDS-C6). METHODS: A total of 2242 subjects from level 1 (citalopram) of the Sequenced Treatment Alternatives to Relieve Depression (STAR* study were included in the analysis. Symptom change, response and remission rates were compared for HAM-D6 versus HAM-D17 and for IDS-C6 versus IDS-C30. The changes in total scores on these scales were compared to the change in Quality of Life Enjoyment and Satisfaction Questionnaire (QLES-Q) score using correlation analysis. RESULTS: The response to treatment was significantly greater according to the HAM-D6 and IDS-C6. Furthermore, the correlation of changes in depression-ratings with changes in QLES-Q scores were comparable for the subscales and full scales. LIMITATIONS: STAR*D was not designed to answer the research questions addressed in this analysis. CONCLUSIONS: Our findings indicate that the HAM-D6 and IDS-C6melancholia scales capture a coherent construct in depression. The syndrome reflected in these scales is unidimensional, sensitive to specific pharmacological intervention, and therefore likely to have biological validity. We therefore believe that "melancholia" thus defined could be a valuable construct under the Research Domain Criteria (RDoC), which specifically aims at identifying the neurobiology underlying mental disorders and providing drugable targets.
Authors: Søren D Østergaard; Maria S Speed; Charles H Kellner; Martina Mueller; Shawn M McClintock; Mustafa M Husain; Georgios Petrides; William V McCall; Sarah H Lisanby Journal: J Affect Disord Date: 2020-05-23 Impact factor: 4.839
Authors: Karen T Putnam; Marsha Wilcox; Emma Robertson-Blackmore; Katherine Sharkey; Veerle Bergink; Trine Munk-Olsen; Kristina M Deligiannidis; Jennifer Payne; Margaret Altemus; Jeffrey Newport; Gisele Apter; Emmanuel Devouche; Alexander Viktorin; Patrik Magnusson; Brenda Penninx; Anne Buist; Justin Bilszta; Michael O'Hara; Scott Stuart; Rebecca Brock; Sabine Roza; Henning Tiemeier; Constance Guille; C Neill Epperson; Deborah Kim; Peter Schmidt; Pedro Martinez; Arianna Di Florio; Katherine L Wisner; Zachary Stowe; Ian Jones; Patrick F Sullivan; David Rubinow; Kevin Wildenhaus; Samantha Meltzer-Brody Journal: Lancet Psychiatry Date: 2017-05-03 Impact factor: 27.083
Authors: Elizabeth D Ballard; Julia S Yarrington; Cristan A Farmer; Marc S Lener; Bashkim Kadriu; Níall Lally; Deonte Williams; Rodrigo Machado-Vieira; Mark J Niciu; Lawrence Park; Carlos A Zarate Journal: J Affect Disord Date: 2018-02-05 Impact factor: 4.839
Authors: Søren D Østergaard; Anthony J Rothschild; Alastair J Flint; Benoit H Mulsant; Ellen M Whyte; Tom Vermeulen; Per Bech; Barnett S Meyers Journal: J Affect Disord Date: 2015-10-22 Impact factor: 4.839
Authors: Lucas Primo de Carvalho Alves; Marcelo Pio de Almeida Fleck; Aline Boni; Neusa Sica da Rocha Journal: PLoS One Date: 2017-01-23 Impact factor: 3.240